About Cabaletta Bio
Cabaletta Bio is a company based in Radnor (United States) founded in 2017. Cabaletta Bio has raised $88.26 million across 2 funding rounds from investors including University of Pennsylvania, Adage Capital Management and 5AM Ventures. The company has 161 employees as of December 31, 2024. Cabaletta Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
- Headquarter Radnor, United States
- Employees 161 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cabaletta Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$115.86 M (USD)-71.21as on Dec 31, 2024
-
EBITDA
-$120.33 M (USD)-64.31as on Dec 31, 2024
-
Total Equity Funding
$88.26 M (USD)
in 2 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 03, 2019
-
Investors
University of Pennsylvania
& 6 more
-
Employee Count
161
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cabaletta Bio
Cabaletta Bio is a publicly listed company on the NASDAQ with ticker symbol CABA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Cabaletta Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Cabaletta Bio
Cabaletta Bio has successfully raised a total of $88.26M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cabaletta Bio
Cabaletta Bio has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Pennsylvania, Adage Capital Management and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Cabaletta Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cabaletta Bio
Investment portfolio details for Cabaletta Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cabaletta Bio
Detailed financials for Cabaletta Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cabaletta Bio Comparisons
Peer comparison for Cabaletta Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cabaletta Bio
Cabaletta Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Cabaletta Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cabaletta Bio
Complete news archive for Cabaletta Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cabaletta Bio
Cabaletta Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Cabaletta Bio is headquartered in Radnor, United States. It is registered at Radnor, Pennsylvania, United States.
Cabaletta Bio is a funded company, having raised a total of $88.26M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cabaletta Bio is 161.
Founded in 2017 and based in Radnor, United States, focus is placed on biotechnology for autoimmune disorders. CAAR T cells are engineered using a CAR-T cell platform to selectively target and eliminate autoantibody-producing B cells. Operations center on advancing this technology through research and development, with applications aimed at B cell-mediated conditions in the immunology sector.
Cabaletta Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Cabaletta Bio is publicly traded on NASDAQ under the ticker symbol CABA.
Cabaletta Bio has 7 investors. Key investors include University of Pennsylvania, Adage Capital Management, 5AM Ventures, Deerfield, and Redmile Group.
The ticker symbol of Cabaletta Bio is CABA on NASDAQ.